NCT03944421

Brief Summary

This study will evaluate the effects of substituting red and processed meat in the diet with Quorn; a meat replacement product, on biomarkers of gut health. This will be a crossover design where participants will take part in 2 study periods where they will consume a diet containing red and processed meat during one of the study periods, whereas in the other study period, they will consume a diet containing Quorn.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable colorectal-cancer

Timeline
Completed

Started Jul 2019

Shorter than P25 for not_applicable colorectal-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 5, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

May 9, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

July 3, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 29, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 29, 2020

Completed
Last Updated

June 1, 2020

Status Verified

May 1, 2019

Enrollment Period

7 months

First QC Date

March 5, 2019

Last Update Submit

May 28, 2020

Conditions

Keywords

GenotoxicityDNA damageGut MicrobiotaMetabolites

Outcome Measures

Primary Outcomes (1)

  • Genotoxic potential of Faecal extracts from volunteers consuming intervention diets rich in red and processed meat versus diets containing Quorn

    Changes in the DNA damage causing capacity of aqueous stool extracts, assessed against HT29 and Caco-2 cells using the Comet assay.

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

Secondary Outcomes (5)

  • Oxidative Damage

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

  • Endogenous Short Chain Fatty Acid Production

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

  • Gut Microbial Composition

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

  • Endogenous Production of Para-Cresol

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

  • Changes in MicroRNA Expression

    2 weeks- Change from baseline following two week intervention with meat versus Quorn consumption

Other Outcomes (2)

  • Blood Cholesterol

    2 weeks

  • Blood Glucose

    2 weeks

Study Arms (2)

Red and Processed Meat

EXPERIMENTAL

240 grams (raw weight) of red and processed meat every day for 2 weeks

Other: Red and Processed Meat

Quorn

EXPERIMENTAL

240 grams (uncooked weight) of Quorn every day for 2 weeks

Other: Quorn

Interventions

Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.

Red and Processed Meat
QuornOTHER

Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.

Also known as: Quorn Food
Quorn

Eligibility Criteria

Age18 Years - 50 Years
Sexmale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male
  • years.
  • Not been diagnosed with colorectal cancer, or adenomas.
  • Habitual omnivorous dietary pattern.
  • BMI ≥18-30 kg/m2.
  • Blood HbA1c \<58mmol/mol (\<6.5%) (not diagnosed with diabetes)
  • Fasting total cholesterol\<7.8 mmol/l
  • Triglycerides \<2.3 mmol/l
  • Normal liver function (assessed by measuring liver enzymes in the screening blood sample).
  • Blood pressure lower than BP \<140/90 mmHg.
  • Not suffering any cardiovascular diseases/ heart diseases e.g. stroke in the past 12 months.
  • Do not suffer from chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, coeliac disease)
  • Do not take supplements or medication that effects gastrointestinal health
  • Not participated in a pre-/probiotic or laxative trial within the previous 3 months.
  • Not been prescribed and/or taken antibiotics in the previous 6 months.
  • +1 more criteria

You may not qualify if:

  • Been diagnosed with colorectal cancer and/or colorectal adenomas.
  • Been diagnosed with gastrointestinal disorders (e.g. Inflammatory bowel disease, irritable bowel syndrome, coeliac disease)
  • Adherence to a dietary pattern which excludes foods from an animal origin.
  • Have history of food intolerances/allergies (e.g. gluten or dairy) or intolerances (e.g. lactose).
  • Taking, or unwilling to stop taking anti-oxidant supplements (e.g. vitamin C, vitamin E, Multivitamin tablets, polyphenol supplements)
  • Received antibiotics in the previous 6 months.
  • Have participated in similar dietary or prebiotic/probiotics study in the previous 3 months.
  • Current smoker.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Northumbria University

Newcastle upon Tyne, Tyne and Wear, NE1 8ST, United Kingdom

Location

Related Publications (2)

  • Farsi DN, Gallegos JL, Finnigan TJA, Cheung W, Munoz JM, Commane DM. The effects of substituting red and processed meat for mycoprotein on biomarkers of cardiovascular risk in healthy volunteers: an analysis of secondary endpoints from Mycomeat. Eur J Nutr. 2023 Dec;62(8):3349-3359. doi: 10.1007/s00394-023-03238-1. Epub 2023 Aug 25.

  • Farsi DN, Gallegos JL, Koutsidis G, Nelson A, Finnigan TJA, Cheung W, Munoz-Munoz JL, Commane DM. Substituting meat for mycoprotein reduces genotoxicity and increases the abundance of beneficial microbes in the gut: Mycomeat, a randomised crossover control trial. Eur J Nutr. 2023 Apr;62(3):1479-1492. doi: 10.1007/s00394-023-03088-x. Epub 2023 Jan 18.

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

Dyrk Kinases

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

Protein Serine-Threonine KinasesProtein KinasesPhosphotransferases (Alcohol Group Acceptor)PhosphotransferasesTransferasesEnzymesEnzymes and CoenzymesProtein-Tyrosine KinasesIntracellular Signaling Peptides and ProteinsProteinsAmino Acids, Peptides, and Proteins

Study Officials

  • daniel M commane, PhD

    Northumbria University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 5, 2019

First Posted

May 9, 2019

Study Start

July 3, 2019

Primary Completion

January 29, 2020

Study Completion

January 29, 2020

Last Updated

June 1, 2020

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will share

De-identified individual participant data for all primary and secondary outcome measures will be made available.

Shared Documents
STUDY PROTOCOL, ICF, CSR
Time Frame
Data will be available within 18 months of study completion
Access Criteria
Northumbria University has plans to acquire a data repository for sharing data in the near future.

Locations